All the news Showing 10 of 914 articlesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Treatment issues Dual hepatitis C therapy improves insulin resistance in HIV/hepatitis C co-infected patients Michael Carter / 16 May 2012 Treatment with pegylated interferon and ribavirin is associated with lasting improvements in insulin resistance among HIV-positive people co-infected with hepatitis C, investigators report in the online edition of Clinical Infectious Diseases. Hepatitis C therapy ... Therapies BI 201335 & BI 207127 and ribavirin shows good efficacy, including hepatitis C patients with cirrhosis Liz Highleyman / 15 May 2012 An interferon-free regimen of the hepatitis C virus (HCV) protease inhibitor BI 201335, the non-nucleoside polymerase inhibitor BI 207127, and ribavirin produced sustained virological response in 68% of previously untreated genotype 1 hepatitis C ... Blood disorders (anaemia, thrombocytopenia and neutropenia) Ribavirin dose reduction is effective for managing anaemia in patients using boceprevir or telaprevir Liz Highleyman / 11 May 2012 Reducing the dose of ribavirin and adding erythropoietin are both good options for managing anaemia in hepatitis C patients treated with boceprevir (Victrelis) triple therapy, according to study findings presented at the 47th ... Therapies Promising findings for therapeutic hepatitis C vaccine TG4040 Liz Highleyman / 09 May 2012 An investigational hepatitis C virus (HCV) therapeutic vaccine significantly improved the likelihood of sustained response to interferon-based therapy, according to a proof-of-concept study reported at the 47th International Liver Congress (EASL 2012) last month ... Treatment issues Depression and pegylated interferon: doctors look at screening strategies and treatment Michael Carter / 09 May 2012 Patients with hepatitis C should be carefully evaluated for symptoms of depression before and during pegylated interferon-based therapy, investigators write in the International Journal of Interferon, Cytokine and Mediator Research. The authors also highlighted ... HIV Co-infection with hepatitis C increases mortality risk by 50% for patients with AIDS Michael Carter / 06 May 2012 Co-infection with hepatitis C increases the risk of death for patients with AIDS by 50%, according to the results of a large study published in the online edition of Clinical Infectious Diseases. ... Hepatocellular carcinoma (HCC) Brivanib did not improve overall liver cancer survival, but did show anti-tumour activity Liz Highleyman / 30 April 2012 The experimental cancer drug brivanib did not lengthen overall survival for patients with hepatocellular carcinoma, but it did increase time to progression, demonstrating that it had anti-tumour activity, researchers reported at the 47th ... Therapies GS-7977 with interferon/ribavirin cures most treatment-naive hepatitis C patients in 12 weeks Liz Highleyman / 30 April 2012 Adding GS-7977 to pegylated interferon and ribavirin for 12 weeks led to a sustained response rate of 90% for previously untreated chronic hepatitis C patients with difficult-to-treat genotype 1, researchers reported at the ... Prognosis and disease progression Chronic hepatitis B infection associated with twice the risk of liver-related death compared to hepatitis C Michael Carter / 27 April 2012 The risk of death due to liver disease is twice as high for patients with chronic hepatitis B infection compared to individuals with chronic hepatitis C, US researchers report in the online edition ... Acute infection Incidence of hepatitis C re-infection and clearance may be understimated Michael Carter / 26 April 2012 The incidence of hepatitis C re-infection among high-risk individuals who have spontaneously cleared the infection may be higher than previously assumed, a modelling study published in the May 1st edition of the ... ← Prev1...8485868788...92Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds